Annular pulmonary artery stimulation ablation catheter

Abstract

The invention relates to an annular pulmonary artery stimulation ablation catheter which comprises a catheter body, a mesh basket, an ablation treatment unit, and a blood pressure monitoring unit, wherein a driving handle is movably installed on the catheter body; the mesh basket is movably arranged on the catheter body and connected with the driving handle, and the mesh basket has a contraction state for avoiding a pulmonary artery opening and an expansion state for being tightly attached to the pulmonary artery opening; the ablation treatment unit is arranged on the catheter body and connected with the mesh basket; and the blood pressure monitoring unit is arranged on the tube body. After a part needing to be ablated is positioned, the ablation treatment unit is started, and then stimulation ablation treatment can be completed; and then the blood pressure changes of the part needing to be ablated are monitored again, and whether ablation takes effect or not can be further judged until the whole circular pulmonary artery ablation treatment operation is completed. Compared with a traditional ablation catheter, the annular pulmonary artery stimulation ablation catheter in the schemecan accurately position the part needing to be ablated through blood pressure monitoring, and the annular pulmonary artery ablation treatment effect and efficiency are greatly improved.

Description

technical field [0001] The invention relates to the technical field of medical devices, in particular to a ring pulmonary artery stimulation ablation catheter. Background technique [0002] Pulmonary hypertension (PH) is a type of malignant pulmonary vascular disease. Its main pathophysiological feature is continuous pulmonary vascular constriction and remodeling, leading to progressive increase in pulmonary vascular resistance and varying degrees of right heart failure. PH refers to elevated pulmonary artery pressure due to various causes, including precapillary PH, postcapillary PH, and mixed PH (increased pulmonary artery and pulmonary venous pressure). In the past 10 years, three major drugs targeting the classic pathway of PH targeted therapy: endothelin receptor antagonists, phosphodiesterase 5 inhibitors, and prostacyclins have been launched successively, and the combined treatment strategy has also been recognized by clinicians. However, these therapeutic drugs have...

AI Technical Summary

Problems solved by technology

[0004] Based on this, it is necessary to provide a circumpulmonary artery stimulating ablation catheter, which aims to solve the problems of slow treatment speed and poor treatment effect in the prior art

Images